### **Touro Scholar**

NYMC Faculty Posters

Faculty

Spring 3-1-2017

### Down-Regulation of Fructose-1, 6-Bisphosphatase-1 (FBP1) in High Grade Urothelial Carcinoma (UC); as a New Diagnostic Marker to Differentiate Nested Variants of Urothelial Carcinoma from Benign Entities

Taliya Farooq *New York Medical College*, taliya\_farooq@nymc.edu

Anas Mashlah New York Medical College, anas\_mashlah@nymc.edu

Faisal Saeed New York Medical College, faisal\_saeed@nymc.edu

Humayun Islam New York Medical College, humayun\_islam@nymc.edu

Jonathan I. Epstein

See next page for additional authors Follow this and additional works at: https://touroscholar.touro.edu/nymc\_fac\_posters Part of the Enzymes and Coenzymes Commons, and the Pathology Commons

#### **Recommended Citation**

Farooq, T., Mashlah, A., Saeed, F., Islam, H., Epstein, J. I., & Zhong, M. (2017). Down-Regulation of Fructose-1, 6-Bisphosphatase-1 (FBP1) in High Grade Urothelial Carcinoma (UC); as a New Diagnostic Marker to Differentiate Nested Variants of Urothelial Carcinoma from Benign Entities. Retrieved from https://touroscholar.touro.edu/nymc\_fac\_posters/16

This Poster is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for inclusion in NYMC Faculty Posters by an authorized administrator of Touro Scholar.For more information, please contact touro.scholar@touro.edu.

#### Authors

Taliya Farooq, Anas Mashlah, Faisal Saeed, Humayun Islam, Jonathan I. Epstein, and Minghao Zhong



# Down-Regulation of Fructose-1, 6-Bisphosphatase-1 (FBP1) in High Grade Urothelial Carcinoma (UC); as a New Diagnostic Marker to Differentiate Nested Variants of Urothelial Carcinoma from **Benign Entities.**

Jonathan I Epstein MD2 and 6. Minghao Zhong M.D., Ph.D.1 University, Pathology, Baltimore, MD.

1. Taliya Farooq MD1, 2. Anas Mashlah M.D1, 3. Faisal Saeed MD1, 4. Islam Humayun M.D/Ph.D1, 5. 1. New York Medical College at Westchester Medical Center, Pathology, Valhalla, NY and 2. Johns Hopkins

# **BACKGROUND:**

Nested variants of urothelial carcinoma are characterized by deceptively bland histomorphology and aggressive clinical behavior. Previously, TERT promoter mutation has been described as specific molecular finding for Nested Variants of Urothelial Carcinoma (NVUC). But to date, no good reliable IHC markers have been discovered to differentiate benign mimickers of NVUC including Von Brunn's Nests (VBN) from NVUC. Recently, loss of FBP1 has been found to be associated with several high grade tumors and may be responsible for Warburg effect at molecular level (Nature, 513:251-5). Fructose-1, 6-bisphosphate is intermediate in glycolysis and its level is mainly controlled by upregulation of fructose-6-phosphate kinase and downregulation of FBP-1. Here, we would like to evaluate the potential role of FBP1 IHC stain to differentiate NVUC from benign entities.


## **DESIGN:**


Tissue microarray slides (TMA) were constructed from 141 cases of UC, including 97 high grade (HG) and 44 low-grade (LG) cases.


We also retrieved Nested (21) and Large Nested (5) variants of urothelial carcinoma from two institutes. The TMA slides and full section slides were subjected to IHC stain for FBP1 (Sigma, 1:100 dilutions). The morphology and FBP-1 staining intensity of urothelial component were carefully examined.

## **RESULTS:**


Normal urothelium are strongly positive for FBP1. 2. Among 141 case of UC from TMA, 79% HG UC and 56% LG UC had decrease or loss of FBP1.







3. Decrease expression or loss of FBP-1 was noticed in 19/21 (90%) NVUC and 4/5 (80%) of LNVUC (nonneoplastic urothelium serves as an internal control.



- high grade UC.
- including VBN.

Murphy WM, Deana DG. The nested variant of transitional cell carcinoma: a neoplasm resembling proliferation of Brunn's nests. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1992; 5(3):240-3.

Chen M, Zhang J. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer; 2011;6(10):e25564. doi: 10.1371/journal.pone.0025564.

WESTCHESTER **MEDICAL CENTER** 

79% of High grade UC	56% of LG UC
19/21 (90%) NVUC	4/5 (80%) of LNVUC

## **CONCLUSIONS:**

1) Loss of FBP1 is associated with UC and especially

2) Loss of FBP-1 can be used as a diagnostic marker to differentiate NVUC from other benign entities

3) Down-regulation of FBP1 may be one of the

mechanisms of urothelial carcinoma to gain cancer cell proliferation and tumourigenicity. It may be

potential target for novel therapy.

## **REFRENCES:**